Poly hydroxyethylmethacrylate polymer poly hema

Manufactured by Santa Cruz Biotechnology

Poly-hydroxyethylmethacrylate polymer (poly-HEMA) is a synthetic, hydrophilic, and biocompatible polymer. It is widely used in various biomedical applications due to its unique physical and chemical properties. The core function of poly-HEMA is to provide a hydrophilic and non-toxic material for the development of various medical devices and biomaterials.

Automatically generated - may contain errors

Lab products found in correlation

P plk1 thr210, by Cell Signaling Technology (2 mentions) Aurora b, by Abcam (2 mentions) β actin, by Santa Cruz Biotechnology (2 mentions) C myc clone 9e10, by Santa Cruz Biotechnology (1 mentions) Aurora a, by Merck Group (1 mentions) Gefitinib, by Chemietek (1 mentions) Erlotinib, by Chemietek (1 mentions) Dacomitinib, by Adooq (1 mentions) Bi2536, by Adooq (1 mentions)

2 protocols using poly hydroxyethylmethacrylate polymer poly hema

Antibody Procurement and Chemical Reagent Acquisition

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies were obtained as follows: p-PLK1 (Thr210) (Cell Signalling Technology); Aurora A (Millipore); Aurora B (Abcam); PLK1 (clone F-8), VCAM-1 (clone H-276), ICAM-1 (clone H-108), Bcl-2 (clone N-19), Bax (clone N-20), survivin (clone FL-142), p21 (clone C-19), cyclin B1 (clone GNS1), Wee1 (clone C-20), CDC25 (clone C-20), c-Myc (clone 9E10) and β-actin (Santa Cruz Biotechnology).
Tivozanib was purchased from AdooQ BioScience (Irvine, CA, USA). Gefitinib (EGFR small molecule inhibitor) and temozolomide (a DNA alkylating agent) were obtained from ChemieTek (Indianapolis, IN, USA). Irinotecan (a topoisomerase I inhibitor) was purchased from pharmacy of Shariati hospital (Tehran, Iran). Poly-hydroxyethylmethacrylate polymer (poly-HEMA) was obtained from Santa Cruz Biotechnology.

Momeny M., Moghaddaskho F., Gortany N.K., Yousefi H., Sabourinejad Z., Zarrinrad G., Mirshahvaladi S., Eyvani H., Barghi F., Ahmadinia L., Ghazi-Khansari M., Dehpour A.R., Amanpour S., Tavangar S.M., Dardaei L., Emami A.H., Alimoghaddam K., Ghavamzadeh A, & Ghaffari S.H. (2017). Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells. Scientific Reports, 7, 44075.

+ Open protocol

+ Expand

Antibody Reagents and Cell Treatment Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies were obtained as follows: Aurora B (Abcam); EGFR, HER2, HER3 (clone 2F12) and HER3-neutralising monoclonal antibody (clone H3.105.5) (Millipore); p-EGFR (Tyr1068), p-HER2 (Tyr1248), p-HER3 (Tyr1289; clone 21D3), p-HER4 (Tyr1284; clone 21A9) and p-PLK1 (Thr210) (Cell Signalling Technology); HER4 (clone C-7), PLK1 (clone F-8), FOXM1 (clone C-20), survivin (clone FL-142) and β-actin (Santa Cruz Biotechnology). Dacomitinib and BI 2536 (a specific inhibitor of polo-like kinase 1) were purchased from Adooq Bioscience (Irvine, CA, USA) and were dissolved in DMSO. The final concentrations of DMSO did not exceed than 0.1% [v/v] in all the treatments. Erlotinib (EGFR small molecule inhibitor) was obtained from Chemietek (Indianapolis, IN, USA). Cetuximab (a ligand-blocking anti-EGFR mAb), trastuzumab (anti-HER2 mAb), cisplatin and doxorubicin (DNA-damaging drugs), paclitaxel (a taxane inhibitor of microtubule disassembly), vincristine (a mitosis-blocking agent), carboplatin (an alkylating agent) and gemcitabine (a nucleoside analogue which inhibits DNA synthesis) were purchased from the pharmacy of Shariati hospital (Tehran, Iran). Poly-hydroxyethylmethacrylate polymer (poly-HEMA) was obtained from Santa Cruz Biotechnology. Recombinant HRGβ-1 was purchased from Peprotech.

Momeny M., Zarrinrad G., Moghaddaskho F., Poursheikhani A., Sankanian G., Zaghal A., Mirshahvaladi S., Esmaeili F., Eyvani H., Barghi F., Sabourinejad Z., Alishahi Z., Yousefi H., Ghasemi R., Dardaei L., Bashash D., Chahardouli B., Dehpour A.R., Tavakkoly-Bazzaz J., Alimoghaddam K., Ghavamzadeh A, & Ghaffari S.H. (2017). Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells. Scientific Reports, 7, 4204.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!